• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    MetaVia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/21/25 8:30:17 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email
    0001638287false00016382872025-05-212025-05-21

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): May 21, 2025

    Graphic

    METAVIA INC.

    (Exact name of Registrant as Specified in Its Charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

    ​

    001-37809

    ​

    47-2389984

    (State or other jurisdiction

    of incorporation)

    ​

    (Commission

    File Number)

    ​

    (IRS Employer

    Identification No.)

    ​

    ​

    ​

    ​

    ​

    ​

    545 Concord Avenue, Suite 210

    Cambridge, Massachusetts

    ​

    ​

    02138

    (Address of principal executive offices)

    ​

    (Zip Code)

    ​

    (857) 702-9600

    (Registrant’s telephone number, including area code)

    ​

    Not applicable

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Title of each class

        

    Trading

    Symbol(s)

        

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    MTVA

     

    The Nasdaq Stock Market LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    ​

    Item 8.01.Other Events.

    ​

    On May 21, 2025, MetaVia Inc. (the “Company”) posted an updated corporate presentation to its website at https://ir.metaviatx.com/events-presentations/presentations, which the Company may use from time to time in connection with presentations, investor communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    ​

    Forward-Looking Statements

    ​

    Exhibit 99.1 attached hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

    ​

    Item 9.01.Financial Statements and Exhibits.

    ​

    (d) Exhibits

    ​

    ​

    ​

    ​

    Exhibit
    Number

        

    Exhibit Description

    99.1

    ​

    Corporate Presentation dated May 21, 2025.

    104

    ​

    Cover Page Interactive Data File (embedded within Inline XBRL document).

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

        

    METAVIA INC.

    ​

    ​

    ​

    ​

    ​

    ​

    Date: May 21, 2025

    ​

    By:

    /s/ Hyung Heon Kim

    ​

    ​

    ​

    Hyung Heon Kim

    ​

    ​

    ​

    President and Chief Executive Officer

    ​

    ​

    ​

    Get the next $MTVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on MetaVia with a new price target

      H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

      12/30/24 7:25:48 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      5/20/25 4:16:39 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      5/20/25 4:16:39 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Woodworth Marshall H covered exercise/tax liability with 3,417 shares, decreasing direct ownership by 10% to 30,079 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      3/4/25 4:01:49 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & President Kim Hyung Heon covered exercise/tax liability with 2,795 shares, decreasing direct ownership by 4% to 61,004 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      3/4/25 4:01:15 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

      MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

      5/20/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, Waist Reduction and Tolerability Additional Cohorts Planned to Determine Maximum Tolerated Dose of DA-1726 Successfully Completed a Private Placement Resulting in $10 Million in Gross Proceeds $11.2 Million in Cash at End of First Quarter, With the Additional $10.0 Million From the Private Placement, is Expected to Fund the Company Into 2026 CAMBRIDGE, Mass., May 14, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial r

      5/14/25 4:05:00 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTVA
    SEC Filings

    See more
    • MetaVia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - MetaVia Inc. (0001638287) (Filer)

      5/30/25 5:06:04 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by MetaVia Inc.

      PRE 14A - MetaVia Inc. (0001638287) (Filer)

      5/27/25 4:16:05 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MetaVia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - MetaVia Inc. (0001638287) (Filer)

      5/21/25 8:30:17 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care